ClinicalTrials.gg
Active, not recruitingNCT05193565Updated Feb 17, 2026

Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients

A Phase 4 interventional study of Sirolimus and Mycophenolate mofetil in Kidney Transplantation, sponsored by Chong Kun Dang Pharmaceutical. Active, not recruiting at 1 site in South Korea. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
206
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and Safety after conversion to RaparoBell® or Myrept® in patients who in renal transplant patients undergoing maintenance therapy with Mycophenolic acid.

Read the detailed description

This study is a multi-center, Randomized, Open-label and phase IV clinical trial that evaluates the efficacy and safety after conversion to RaparoBell® or Myrept® administration for 24 weeks in renal transplant patients undergoing maintenance therapy with Mycophenolic acid.

02

Conditions studied

  • Kidney Transplantation

Keywords

  • Kidney Transplantation
  • Sirolimus
03

In context

Lead sponsor

Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who at least 1 year and less than 10 years after kidney transplantation
  2. Over 20 years old
  3. Patients on maintenance therapy using combination of Calcineurin Inhibitor and Mycophenolic acid after kidney transplantation

Exclusion criteria

Exclusion Criteria:

  1. Patients who have transplanted organs other than kidney
  2. At the time of Screening

    • Treatment with active liver disease or Liver function test(T-, , ALT)is over 3 times than upper normal limit
    • WBC\< 2,500/mm\^3, or \< 75,000/mm\^3, or ANC \< 1,300/ mm\^3
    • Protein/Creatinine ratio≥1.0(mg/mg)
  3. Patents who had a record of taking mTOR inhibitor before 3 months
  4. In investigator's judgement
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
206 participants (estimated)

Study arms

  • Experimental
    RaparoBell Tablet

    RaparoBell Tablet

    Drug: Sirolimus

  • Active comparator
    Mycophenolate Mofetil Tablet/Capsule

    Myrept Tablet/Capsule

    Drug: Mycophenolate mofetil

Interventions

  • Orally, once-daily in the morning - Check the blood concentration of Sirolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~8ng/mL

    Also known as: RaparoBell® Tab.

  • Up to 1g BID(total 2g daily), PO

    Also known as: Myrept® Cap./Tab.

06

What researchers measure

Primary outcomes

  1. Incidence of composite efficacy failure

    Composite efficacy failure include biopsy-confirmed acute rejection, graft loss, death, or follow-up failure

    Time frame: Until 24 weeks

Secondary outcomes

  1. Incidence of biopsy-confirmed acute rejection(TCMR, AMR)

    The frequency and Incidence

    Time frame: Until 24 weeks

  2. Pathologic Results, Occurrence, Treatment Methods, and Results of Acute Rejection Confirmed by Biopsy

    By Banff classification categories

    Time frame: Until 24 weeks

  3. Survival rate of transplanted organ

    Kaplan-Meier

    Time frame: Until 24 weeks

  4. Survival rate of Patients

    Kaplan-Meier

    Time frame: Until 24 weeks

  5. Serum-Cr, eGFR

    eGFR using MDRD

    Time frame: Until 24 weeks

  6. Incidence of BKV, CMV infection

    The frequency and Incidence

    Time frame: Until 24 weeks

07

Study locations

1 site
  • Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, South Korea
    Seoul, South Korea
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2021 (actual). Primary completion is estimated for Jul 2026, 56 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2022
First posted
Jan 18, 2022
StartActual
Nov 19, 2021
Primary completionEst.
Jul 2026
CompletionEst.
Nov 2026
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05193565
Responsible party
Sponsor
First posted
Jan 18, 2022
Start date
Nov 19, 2021
Primary completion
Jul 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Feb 17, 2026

Study contacts

Jae Berm Park, Ph.D
study chair · Samsung Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion